VIDEO: Pacritinib ‘can outperform’ ruxolitinib in patients with low platelet counts
Click Here to Manage Email Alerts
Aaron T. Gerds, MD, MS, speaks with Healio about the challenge dosing for ruxolitinib in patients with thrombocytopenia and the development of pacritinib as a Janus kinase inhibitor “specifically for patients with low platelet counts.”
Gerds, assistant professor of medicine at Cleveland Clinic Taussig Cancer Institute and medical director of Case Comprehensive Cancer Center, discussed findings from a head-to-head trial, presented at ASH Annual Meeting and Exposition, between pacritinib and ruxolitinib (Opzelura, Incyte) among patients with myelofibrosis and moderate-to-severe thrombocytopenia.
“What these abstracts suggest is that pacritinib can outperform ruxolitinib in this particular population,” he said.
Reference
- Mascarenhas J, et al. Abstract 3639. Presented at: ASH Annual Meeting & Exposition; Dec. 11-14, 2021; Atlanta.
Collapse
Healio Interview
Click Here to Manage Email Alerts